<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587079</url>
  </required_header>
  <id_info>
    <org_study_id>PT003005</org_study_id>
    <nct_id>NCT01587079</nct_id>
  </id_info>
  <brief_title>Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomized, Double Blind, (Test Products), Chronic Dosing (7 Days), Four Period, Eight Treatment , Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Five Doses of PT003, One Dose of PT001 and One Dose of PT005 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open Label) as Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol
      Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate
      to severe COPD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC 0-12 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>FEV1 AUC 0-12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 on Treatment Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change from Baseline in FEV1 on Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to onset of action (&gt;10% improvement in FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving &gt;=12% Improvement in FEV1 on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of subjects achieving &gt;=12% improvement in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in Inspiratory Capacity on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change from baseline in Inspiratory Capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline in FEV1 Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough IC on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in morning pre-dose trough IC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline IC on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline IC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Evening 12-hour Post-dose Trough FEV1 on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline at evening 12-hour post-dose trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning Pre-dose Daily Peak Flow Readings on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean morning pre-dose daily peak flow readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning Post-dose Daily Peak Flow Readings on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean morning post-dose daily peak flow readings on</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Pre-dose Daily Peak Flow Readings on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean evening pre-dose daily peak flow readings (BID treatments only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Post-dose Daily Peak Flow Readings on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean evening post-dose daily peak flow readings (12 Hours post-dose for Spiriva)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT003 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva® Handihaler®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003</intervention_name>
    <description>PT003 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT003 (Dose 1)</arm_group_label>
    <arm_group_label>PT003 (Dose 2)</arm_group_label>
    <arm_group_label>PT003 (Dose 3)</arm_group_label>
    <arm_group_label>PT003 (Dose 4)</arm_group_label>
    <arm_group_label>PT003 (Dose 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001</intervention_name>
    <description>PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005</intervention_name>
    <description>PT005 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium inhalation powder</intervention_name>
    <description>Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days</description>
    <arm_group_label>Spiriva® Handihaler®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post-bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post-bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2012</study_first_posted>
  <results_first_submitted>May 23, 2016</results_first_submitted>
  <results_first_submitted_qc>May 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2016</results_first_posted>
  <disposition_first_submitted>October 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 14, 2013</disposition_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 20 sites in the US from May 2012 until September 2012. The entire study was scheduled to take a maximum of 19 weeks for each individual subject.</recruitment_details>
      <pre_assignment_details>Study was a chronic dosing (7 days), 4-period, 8-treatment, Incomplete Block, Cross-Over.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT/Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects Screened</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age, years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83" spread="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC 0-12 on Day 7</title>
        <description>FEV1 AUC 0-12</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 μg (PT001)</title>
            <description>18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 18/9.6 μg (PT003)</title>
            <description>18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI 9/9.6 μg</title>
            <description>9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI 2.4/9.6 μg (PT003)</title>
            <description>2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI 1.2/9.6 μg (PT003)</title>
            <description>1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI 9.6 μg</title>
            <description>9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 0-12 on Day 7</title>
          <description>FEV1 AUC 0-12</description>
          <population>MITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="57"/>
                <count group_id="O8" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.452" lower_limit="1.415" upper_limit="1.489"/>
                    <measurement group_id="O2" value="1.591" lower_limit="1.554" upper_limit="1.628"/>
                    <measurement group_id="O3" value="1.547" lower_limit="1.509" upper_limit="1.585"/>
                    <measurement group_id="O4" value="1.539" lower_limit="1.502" upper_limit="1.575"/>
                    <measurement group_id="O5" value="1.538" lower_limit="1.502" upper_limit="1.575"/>
                    <measurement group_id="O6" value="1.508" lower_limit="1.472" upper_limit="1.545"/>
                    <measurement group_id="O7" value="1.467" lower_limit="1.430" upper_limit="1.505"/>
                    <measurement group_id="O8" value="1.489" lower_limit="1.453" upper_limit="1.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 on Treatment Day 1</title>
        <description>Peak change from Baseline in FEV1 on Treatment</description>
        <time_frame>Day 1</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 on Treatment Day 1</title>
          <description>Peak change from Baseline in FEV1 on Treatment</description>
          <population>MITT</population>
          <units>Milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="172" upper_limit="246"/>
                    <measurement group_id="O2" value="339" lower_limit="302" upper_limit="376"/>
                    <measurement group_id="O3" value="329" lower_limit="292" upper_limit="367"/>
                    <measurement group_id="O4" value="348" lower_limit="311" upper_limit="386"/>
                    <measurement group_id="O5" value="333" lower_limit="296" upper_limit="370"/>
                    <measurement group_id="O6" value="312" lower_limit="275" upper_limit="349"/>
                    <measurement group_id="O7" value="317" lower_limit="280" upper_limit="355"/>
                    <measurement group_id="O8" value="238" lower_limit="201" upper_limit="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1</title>
        <description>Time to onset of action (&gt;10% improvement in FEV1)</description>
        <time_frame>Day 1</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action (&gt;10% Improvement in FEV1) on Day 1</title>
          <description>Time to onset of action (&gt;10% improvement in FEV1)</description>
          <population>MITT</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="66"/>
                    <measurement group_id="O7" value="60"/>
                    <measurement group_id="O8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No onset within 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving &gt;=12% Improvement in FEV1 on Day 1</title>
        <description>Proportion of subjects achieving &gt;=12% improvement in FEV1</description>
        <time_frame>Day 1</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>GP MDI 18 μg (PT001)</title>
            <description>18 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving &gt;=12% Improvement in FEV1 on Day 1</title>
          <description>Proportion of subjects achieving &gt;=12% improvement in FEV1</description>
          <population>MITT</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="83"/>
                    <measurement group_id="O7" value="80"/>
                    <measurement group_id="O8" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in Inspiratory Capacity on Day 1</title>
        <description>Peak change from baseline in Inspiratory Capacity</description>
        <time_frame>Day 1</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in Inspiratory Capacity on Day 1</title>
          <description>Peak change from baseline in Inspiratory Capacity</description>
          <population>MITT</population>
          <units>Milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" lower_limit="131" upper_limit="278"/>
                    <measurement group_id="O2" value="393" lower_limit="320" upper_limit="467"/>
                    <measurement group_id="O3" value="320" lower_limit="244" upper_limit="397"/>
                    <measurement group_id="O4" value="387" lower_limit="313" upper_limit="461"/>
                    <measurement group_id="O5" value="347" lower_limit="274" upper_limit="421"/>
                    <measurement group_id="O6" value="348" lower_limit="276" upper_limit="420"/>
                    <measurement group_id="O7" value="335" lower_limit="261" upper_limit="409"/>
                    <measurement group_id="O8" value="233" lower_limit="160" upper_limit="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 on Day 7</title>
        <description>Change from baseline in morning pre-dose trough FEV1</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 on Day 7</title>
          <description>Change from baseline in morning pre-dose trough FEV1</description>
          <population>MITT</population>
          <units>Milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="87" upper_limit="152"/>
                    <measurement group_id="O2" value="183" lower_limit="151" upper_limit="216"/>
                    <measurement group_id="O3" value="150" lower_limit="117" upper_limit="184"/>
                    <measurement group_id="O4" value="154" lower_limit="121" upper_limit="186"/>
                    <measurement group_id="O5" value="163" lower_limit="130" upper_limit="195"/>
                    <measurement group_id="O6" value="130" lower_limit="98" upper_limit="162"/>
                    <measurement group_id="O7" value="104" lower_limit="71" upper_limit="137"/>
                    <measurement group_id="O8" value="122" lower_limit="90" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 on Day 7</title>
        <description>Peak change from baseline in FEV1 Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 on Day 7</title>
          <description>Peak change from baseline in FEV1 Day 7</description>
          <population>MITT</population>
          <units>Millliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="257" upper_limit="342"/>
                    <measurement group_id="O2" value="444" lower_limit="402" upper_limit="487"/>
                    <measurement group_id="O3" value="414" lower_limit="370" upper_limit="458"/>
                    <measurement group_id="O4" value="403" lower_limit="361" upper_limit="446"/>
                    <measurement group_id="O5" value="388" lower_limit="345" upper_limit="430"/>
                    <measurement group_id="O6" value="363" lower_limit="321" upper_limit="404"/>
                    <measurement group_id="O7" value="332" lower_limit="289" upper_limit="375"/>
                    <measurement group_id="O8" value="309" lower_limit="267" upper_limit="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough IC on Day 7</title>
        <description>Change from baseline in morning pre-dose trough IC</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough IC on Day 7</title>
          <description>Change from baseline in morning pre-dose trough IC</description>
          <population>MITT</population>
          <units>Millliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="46" upper_limit="171"/>
                    <measurement group_id="O2" value="185" lower_limit="123" upper_limit="246"/>
                    <measurement group_id="O3" value="183" lower_limit="119" upper_limit="247"/>
                    <measurement group_id="O4" value="215" lower_limit="153" upper_limit="278"/>
                    <measurement group_id="O5" value="203" lower_limit="141" upper_limit="265"/>
                    <measurement group_id="O6" value="151" lower_limit="89" upper_limit="212"/>
                    <measurement group_id="O7" value="129" lower_limit="67" upper_limit="191"/>
                    <measurement group_id="O8" value="106" lower_limit="45" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline IC on Day 7</title>
        <description>Peak change from baseline IC</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline IC on Day 7</title>
          <description>Peak change from baseline IC</description>
          <population>MITT</population>
          <units>Millliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" lower_limit="149" upper_limit="297"/>
                    <measurement group_id="O2" value="430" lower_limit="357" upper_limit="503"/>
                    <measurement group_id="O3" value="441" lower_limit="366" upper_limit="516"/>
                    <measurement group_id="O4" value="409" lower_limit="335" upper_limit="484"/>
                    <measurement group_id="O5" value="368" lower_limit="294" upper_limit="441"/>
                    <measurement group_id="O6" value="371" lower_limit="298" upper_limit="444"/>
                    <measurement group_id="O7" value="377" lower_limit="303" upper_limit="452"/>
                    <measurement group_id="O8" value="241" lower_limit="168" upper_limit="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Evening 12-hour Post-dose Trough FEV1 on Day 7</title>
        <description>Change from baseline at evening 12-hour post-dose trough FEV1</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI BID 18 μg</title>
            <description>BID 18 μg</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI BID 1.2/9.6 μg</title>
            <description>BID 1.2/9.6 μg</description>
          </group>
          <group group_id="O7">
            <title>FF MDI BID 9.6 μg</title>
            <description>BID 9.6 μg</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Evening 12-hour Post-dose Trough FEV1 on Day 7</title>
          <description>Change from baseline at evening 12-hour post-dose trough FEV1</description>
          <population>MITT</population>
          <units>Millliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="53" upper_limit="145"/>
                    <measurement group_id="O2" value="196" lower_limit="151" upper_limit="241"/>
                    <measurement group_id="O3" value="162" lower_limit="115" upper_limit="209"/>
                    <measurement group_id="O4" value="118" lower_limit="73" upper_limit="163"/>
                    <measurement group_id="O5" value="133" lower_limit="87" upper_limit="179"/>
                    <measurement group_id="O6" value="110" lower_limit="65" upper_limit="155"/>
                    <measurement group_id="O7" value="73" lower_limit="28" upper_limit="119"/>
                    <measurement group_id="O8" value="130" lower_limit="85" upper_limit="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning Pre-dose Daily Peak Flow Readings on Day 7</title>
        <description>Change from baseline in mean morning pre-dose daily peak flow readings</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 μg BID</title>
            <description>18 μg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 18/9.6 μg BID</title>
            <description>18/9.6 μg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI 9/9.6 μg BID</title>
            <description>9/9.6 μg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI 2.4/9.6 μg BID</title>
            <description>2.4/9.6 μg BID</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI 1.2/9.6 μg BID</title>
            <description>1.2/9.6 μg BID</description>
          </group>
          <group group_id="O7">
            <title>FF MDI 9.6 μg BID</title>
            <description>9.6 μg BID</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning Pre-dose Daily Peak Flow Readings on Day 7</title>
          <description>Change from baseline in mean morning pre-dose daily peak flow readings</description>
          <population>MITT</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="0.5" upper_limit="14.8"/>
                    <measurement group_id="O2" value="25.2" lower_limit="18.1" upper_limit="32.4"/>
                    <measurement group_id="O3" value="16.6" lower_limit="9.4" upper_limit="23.9"/>
                    <measurement group_id="O4" value="12.4" lower_limit="5.2" upper_limit="19.5"/>
                    <measurement group_id="O5" value="18.0" lower_limit="10.9" upper_limit="25.1"/>
                    <measurement group_id="O6" value="13.8" lower_limit="6.7" upper_limit="20.8"/>
                    <measurement group_id="O7" value="8.6" lower_limit="1.5" upper_limit="15.7"/>
                    <measurement group_id="O8" value="11.6" lower_limit="4.5" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning Post-dose Daily Peak Flow Readings on Day 7</title>
        <description>Change from baseline in mean morning post-dose daily peak flow readings on</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 μg BID</title>
            <description>18 μg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI BID 18/9.6 μg</title>
            <description>BID 18/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI BID 9/9.6 μg</title>
            <description>BID 9/9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg</title>
            <description>4.6/9.6 μg</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI BID 2.4/9.6 μg</title>
            <description>BID 2.4/9.6 μg</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI 1.2/9.6 μg BID</title>
            <description>1.2/9.6 μg BID</description>
          </group>
          <group group_id="O7">
            <title>FF MDI 9.6 μg BID</title>
            <description>9.6 μg BID</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning Post-dose Daily Peak Flow Readings on Day 7</title>
          <description>Change from baseline in mean morning post-dose daily peak flow readings on</description>
          <population>MITT</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="23.0" upper_limit="39.0"/>
                    <measurement group_id="O2" value="58.8" lower_limit="50.9" upper_limit="66.7"/>
                    <measurement group_id="O3" value="55.0" lower_limit="46.9" upper_limit="63.1"/>
                    <measurement group_id="O4" value="46.7" lower_limit="38.8" upper_limit="54.6"/>
                    <measurement group_id="O5" value="52.1" lower_limit="44.1" upper_limit="60.0"/>
                    <measurement group_id="O6" value="49.6" lower_limit="41.7" upper_limit="57.4"/>
                    <measurement group_id="O7" value="43.2" lower_limit="35.3" upper_limit="51.1"/>
                    <measurement group_id="O8" value="37.9" lower_limit="30.0" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Pre-dose Daily Peak Flow Readings on Day 7</title>
        <description>Change from baseline in mean evening pre-dose daily peak flow readings (BID treatments only)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 μg BID</title>
            <description>18 μg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 18/9.6 μg BID</title>
            <description>18/9.6 μg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI 9/9.6 μg BID</title>
            <description>9/9.6 μg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 4.6/9.6 μg BID</title>
            <description>4.6/9.6 μg BID</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI 2.4/9.6 μg BID</title>
            <description>2.4/9.6 μg BID</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI 1.2/9.6 μg BID</title>
            <description>1.2/9.6 μg BID</description>
          </group>
          <group group_id="O7">
            <title>FF MDI 9.6 μg BID</title>
            <description>9.6 μg BID</description>
          </group>
          <group group_id="O8">
            <title>Spiriva18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Pre-dose Daily Peak Flow Readings on Day 7</title>
          <description>Change from baseline in mean evening pre-dose daily peak flow readings (BID treatments only)</description>
          <population>MITT</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="4.6" upper_limit="18.7"/>
                    <measurement group_id="O2" value="32.5" lower_limit="25.4" upper_limit="39.5"/>
                    <measurement group_id="O3" value="25.0" lower_limit="18.0" upper_limit="32.1"/>
                    <measurement group_id="O4" value="19.0" lower_limit="12.0" upper_limit="26.0"/>
                    <measurement group_id="O5" value="25.6" lower_limit="18.7" upper_limit="32.5"/>
                    <measurement group_id="O6" value="19.9" lower_limit="13.0" upper_limit="26.8"/>
                    <measurement group_id="O7" value="16.5" lower_limit="9.6" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Post-dose Daily Peak Flow Readings on Day 7</title>
        <description>Change from baseline in mean evening post-dose daily peak flow readings (12 Hours post-dose for Spiriva)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 18 μg BID</title>
            <description>18 μg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 18/9.6 μg BID</title>
            <description>18/9.6 μg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF/MDI 9/9.6 μg BID</title>
            <description>9/9.6 μg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI BID 4.6/9.6 μg BID</title>
            <description>4.6/9.6 μg BID</description>
          </group>
          <group group_id="O5">
            <title>GFF MDI 2.4/9.6 μg BID</title>
            <description>2.4/9.6 μg BID</description>
          </group>
          <group group_id="O6">
            <title>GFF MDI 1.2/9.6 μg BID</title>
            <description>1.2/9.6 μg BID</description>
          </group>
          <group group_id="O7">
            <title>FF MDI 9.6 μg BID</title>
            <description>9.6 μg BID</description>
          </group>
          <group group_id="O8">
            <title>Spiriva 18 μg QD</title>
            <description>18 μg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Post-dose Daily Peak Flow Readings on Day 7</title>
          <description>Change from baseline in mean evening post-dose daily peak flow readings (12 Hours post-dose for Spiriva)</description>
          <population>MITT</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="63"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="26.8" upper_limit="43.2"/>
                    <measurement group_id="O2" value="61.5" lower_limit="53.1" upper_limit="69.8"/>
                    <measurement group_id="O3" value="56.1" lower_limit="47.8" upper_limit="64.3"/>
                    <measurement group_id="O4" value="51.5" lower_limit="43.3" upper_limit="59.7"/>
                    <measurement group_id="O5" value="53.7" lower_limit="45.6" upper_limit="61.7"/>
                    <measurement group_id="O6" value="53.8" lower_limit="45.8" upper_limit="61.8"/>
                    <measurement group_id="O7" value="48.3" lower_limit="40.3" upper_limit="56.4"/>
                    <measurement group_id="O8" value="30.3" lower_limit="22.2" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and AEs were collected throughout study participation and up to 14 days following the last dose of study drug.</time_frame>
      <desc>Safety Population - All subjects who were randomized, received at least 1 dose of a study treatment, and had a post-baseline safety assessment for that treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>GP MDI 18 μg (PT001)</title>
          <description>18 μg</description>
        </group>
        <group group_id="E2">
          <title>GFF MDI 18/9.6 μg (PT003)</title>
          <description>18/9.6 μg</description>
        </group>
        <group group_id="E3">
          <title>GFF MDI 9/9.6 μg (PT003)</title>
          <description>9/9.6 μg</description>
        </group>
        <group group_id="E4">
          <title>GFF MDI 4.6/9.6 μg (PT003)</title>
          <description>4.6/9.6 μg</description>
        </group>
        <group group_id="E5">
          <title>GFF MDI 2.4/9.6 μg (PT003)</title>
          <description>2.4/9.6 μg</description>
        </group>
        <group group_id="E6">
          <title>GFF MDI 1.2/9.6 μg (PT003)</title>
          <description>1.2/9.6 μg</description>
        </group>
        <group group_id="E7">
          <title>FF MDI 9.6 μg (PT005)</title>
          <description>9.6 μg</description>
        </group>
        <group group_id="E8">
          <title>Spiriva</title>
          <description>18 μg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Resiner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>973-975-0320</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

